Blood · 2005 · 174 citations · 19 references
MedicineHematologyPediatricsClinical ImmunologyPediatric HematologyPediatric ImmunologyAnemiaImmunosuppressionImmunosuppressive AgentsImmunosuppressive TherapyInduction ImmunosuppressionPediatric Clinical ImmunologyAplastic Anemia In ChildrenAplastic CrisisAplastic Marrow FailureImmunosuppressive Drug TherapyPediatric Anemia ManagementPediatric Bone Marrow DisordersSystemic Immunosuppressive Therapy
Severe acquired aplastic anaemia (SAA) is a life-threatening disease characterized by pancytopenia and hypoplastic bone marrow. Autologous T lymphocytes are thought to cause bone marrow failure by immune-mediated excessive apoptosis of stem and progenitor cells. The disease is subclassified into a severe (neutrophil count, > 0.2 x 10(9)/L [> 200/microL]) and a very severe (< 0.2 x 10(9)/L [< 200/microL]) (vSAA) form. We report the results of a prospective multicenter trial with a combined immunosuppressive regimen of cyclosporin A (CSA), anti-thymocyte globulin (ATG) and, in cases with neutrophil counts fewer than 0.5 x 10(9)/L (< 500/microL), granulocyte colony-stimulating factor (G-CSF) for treatment of SAA in children. Children with vSAA showed a higher rate of complete response than did children with SAA (68% versus 45%; P = .009), as well as better survival (93% versus 81%; P < .001). Thus, in children with SAA a more severe disease stage at diagnosis indicates a favorable outcome with immunosuppressive therapy.
19
Antithymocyte Globulin and Cyclosporine for Severe Aplastic Anemia
Stephen J. Rosenfeld, Dean Follmann, Olga Núñez et al. · JAMA · 2003 · 395 citations · Full text
Selection of patients for bone marrow transplantation in severe aplastic anemia
BM Camitta, JM Rappeport, Robertson Parkman et al. · Blood · 1975 · 306 citations · Full text